Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
US9045544B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9045544-B2 |
| Application number | US-201113697699-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 27, 2011 |
| Priority date | May 28, 2010 |
| Publication date | Jun 2, 2015 |
| Grant date | Jun 2, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A preparation comprising an isolated anti-CD160 antibody and an anti-VEGF antibody, wherein said anti-CD160 antibody is selected from the group consisting of CL1-R2 monoclonal antibody, chimeric CL1-R2 antibody, humanized CL1-R2 antibody, and antigen-binding fragments thereof.
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9045544B2 cover?
- The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.
- Who is the assignee on this patent?
- Le Bouteiller Philippe, Bensussan Armand, Inst Nat Sante Rech Med, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).